2019., A. I. o. H. a. W. C. i. A. (2019). Cancer in Australia 2019. Cancer series no.119., Cat. no. CAN 123. Canberra: AIHW.

Abbaszadegan MR, Futscher BW, Klimecki WT, List A, Dalton WS. Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells. Cancer Res. 1994;54(17):4676–9.

CAS  PubMed  Google Scholar 

Abildgaard, N., Bentzen, S. M., Nielsen, J. L., & Heickendorff, L. (1997). Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Nordic Myeloma Study Group (NMSG). Br J Haematol, 96(1), 103–110.

Agarwal JR, Matsui W. Multiple myeloma: a paradigm for translation of the cancer stem cell hypothesis. Anticancer Agents Med Chem. 2010;10(2):116–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alexandrakis M, Passam F, Ganotakis E, Sfiridaki K, Xilouri I, Perisinakis K, Kyriakou D. The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma. Clin Lab Haematol. 2003;25(1):41–6.

Article  CAS  PubMed  Google Scholar 

Auwerda J, Yuana Y, Osanto S, de Maat M, Sonneveld P, Bertina R, Leebeek F. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost. 2011;105(1):14–20.

Article  CAS  PubMed  Google Scholar 

Bao Q-P, Li H-M, Li X-J, Yan Y-H. Biological characteristics of side population cells in multiple myeloma U266 cell line in relation to drug resistance. Chinese Journal of Tissue Engineering Research. 2017;21(29):4648.

Google Scholar 

Bartl R, Frisch B, Diem H, Mundel M, Nagel D, Lamerz R, Fateh-Moghadam A. Histologic, biochemical, and clinical parameters for monitoring multiple myeloma. Cancer. 1991;68(10):2241–50.

Article  CAS  PubMed  Google Scholar 

Bayer-Garner IB, Sanderson RD, Dhodapkar MV, Owens RB, Wilson CS. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod Pathol. 2001;14(10):1052–8. https://doi.org/10.1038/modpathol.3880435.

Article  CAS  PubMed  Google Scholar 

Bebawy M, Combes V, Lee E, Jaiswal R, Gong J, Bonhoure A, Grau GE. Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells. Leukemia. 2009;23(9):1643–9. https://doi.org/10.1038/leu.2009.76.

Article  CAS  PubMed  Google Scholar 

Benameur T, Chappard D, Fioleau E, Andriantsitohaina R, Martinez MC, Clere N, Marchand-Libouban H. Plasma cells release membrane microparticles in a mouse model of multiple myeloma. Micron. 2013;54–55:75–81. https://doi.org/10.1016/j.micron.2013.08.010.

Article  CAS  PubMed  Google Scholar 

Berenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, Mills GM, Salmon SE. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood. 2002;99(9):3163–8. https://doi.org/10.1182/blood.v99.9.3163.

Article  CAS  PubMed  Google Scholar 

Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 1999;68(1):729–77. https://doi.org/10.1146/annurev.biochem.68.1.729.

Article  CAS  PubMed  Google Scholar 

Bernfield M, Kokenyesi R, Kato M, Hinkes M, Spring J, Gallo R, Lose E. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol. 1992;8(1):365–93.

Article  CAS  PubMed  Google Scholar 

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.

Article  PubMed  Google Scholar 

Brown R, Joshua D, Nelson M, Gibson J, Dunn J, MacLennan I. Serum thymidine kinase as a prognostic indicator for patients with multiple myeloma: results from the MRC (UK) V trial. Br J Haematol. 1993;84(2):238–41.

Article  CAS  PubMed  Google Scholar 

Brown, R. D., Joshua, D. E., Nelson, M., Gibson, J., Dunn, J., & MacLennan, I. C. M. Serum thymidine kinase as a prognostic indicator for patients with multiple myeloma: results from the MRC (UK) V Trial.

Bryant C, Suen H, Brown R, Yang S, Favaloro J, Aklilu E, Joshua DE. Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer J. 2013;3: e148. https://doi.org/10.1038/bcj.2013.34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Caivano A, La Rocca F, Laurenzana I, Trino S, De Luca L, Lamorte D, Musto P. Extracellular vesicles in hematological malignancies: from biology to therapy. Int J Mol Sci. 2017;18(6):1183.

Article  PubMed  PubMed Central  Google Scholar 

Callaghan R, Luk F, Bebawy M. Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy? Drug Metab Dispos. 2014;42(4):623–31. https://doi.org/10.1124/dmd.113.056176.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Castellana D, Toti F, Freyssinet J-M. Membrane microvesicles: macromessengers in cancer disease and progression. Thromb Res. 2010;125:S84–8.

Article  PubMed  Google Scholar 

Chapman, M. A., Lawrence, M. S., Keats, J. J., Cibulskis, K., Sougnez, C., Schinzel, A. C., . . . Adli, M. (2011). Initial genome sequencing and analysis of multiple myeloma. nature, 471(7339), 467–472.

Chatterjee G, Gujral S, Subramanian PG, Tembhare PR. Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders. Indian J Hematol Blood Transfus. 2017;33(3):303–15. https://doi.org/10.1007/s12288-017-0822-z.

Article  PubMed  PubMed Central  Google Scholar 

Ching T, Duncan ME, Newman-Eerkes T, McWhorter MM, Tracy JM, Steen MS, Vignali M. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. BMC Cancer. 2020;20(1):1–15.

Article  Google Scholar 

Coppola A, Tufano A, Di Capua M, Franchini M. Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. Semin Thromb Hemost. 2011;37(8):929–45. https://doi.org/10.1055/s-0031-1297372.

Article  PubMed  Google Scholar 

Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, Fitzmaurice C. Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018;4(9):1221–7. https://doi.org/10.1001/jamaoncol.2018.2128.

Article  PubMed  PubMed Central  Google Scholar 

Cuzick J, Cooper E, MacLennan I. The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis. Br J Cancer. 1985;52(1):1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

D’Anastasi M, Notohamiprodjo M, Schmidt GP, Dürr H-R, Reiser MF, Baur-Melnyk A. Tumor Load in Patients With Multiple Myeloma: β2-Microglobulin Levels Versus Whole-Body MRI. Am J Roentgenol. 2014;203(4):854–62.

Article  Google Scholar 

Davies F, Jack A, Morgan G. The use of biological variables to predict outcome in multiple myeloma. Br J Haematol. 1997;99(4):719–25.

Article  CAS  PubMed  Google Scholar 

De Luca L, Laurenzana I, Trino S, Lamorte D, Caivano A, Musto P. An update on extracellular vesicles in multiple myeloma: A focus on their role in cell-to-cell cross-talk and as potential liquid biopsy biomarkers. Expert Rev Mol Diagn. 2019;19(3):249–58.

Article  PubMed  Google Scholar 

De Rubis G, Rajeev Krishnan S, Bebawy M. Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis. Trends Pharmacol Sci. 2019;40(3):172–86. https://doi.org/10.1016/j.tips.2019.01.006.

Article  CAS  PubMed  Google Scholar 

del Conde I, Shrimpton CN, Thiagarajan P, López JA. Tissue-factor–bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood. 2005;106(5):1604–11.

Article  PubMed  Google Scholar 

Dhodapkar MV, Kelly T, Theus A, Athota AB, Barlogie B, Sanderson RD. Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. Br J Haematol. 1997;99(2):368–71.

Article  CAS  PubMed  Google Scholar 

Dimopoulos MA, Barlogie B, Smith TL, Alexanian R. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med. 1991;115(12):931–5.

Article  CAS  PubMed  Google Scholar 

Duhem C, Ries F, Dicato M. What Does Multidrug Resistance (MDR) Expression Mean in the Clinic? Oncologist. 1996;1(3):151–8.

Article  CAS  PubMed  Google Scholar 

Elomaa I, Virkkunen P, Risteli L, Risteli J. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer. 1992;66(2):337.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, Woywodt A, Haubitz M. Diagnostic role of endothelial microparticles in vasculitis. Rheumatology. 2008;47(12):1820–5. https://doi.org/10.1093/rheumatology/ken373.

Article  CAS  PubMed  Google Scholar 

Fisher, G. A., Lum, B. L., Hausdorff, J., & Sikic, B. I. (1996). Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer, 32a(6), 1082–1088. doi:https://doi.org/10.1016/0959-8049(96)00111-6

Fitzgerald ML, Wang Z, Park PW, Murphy G, Bernfield M. Shedding of syndecan-1 and-4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3–sensitive metalloproteinase. J Cell Biol. 2000;148(4):811–24.

Article  CAS  PubMed